RT Journal Article
ID 4431255e7f1c66fe
A1 Saraf, Shivani 
A1 Jain, Ankit
A1 Hurkat, Pooja 
A1 Jain, Sanjay Kumar 
T1 Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform
JF Critical Reviews™ in Therapeutic Drug Carrier Systems
JO CRT
YR 2016
FD 2016-11-02
VO 33
IS 5
SP 401
OP 432
K1 topotecan
K1 camptothecin
K1 liposomes
K1 cancer
K1 accelerated blood clearance
K1 multidrug resistance
AB Topotecan (TPT), a potent anticancer camptothecin analog, is well described for the treatment of ovarian cancer, but has also anticancer activity against small-cell and non-small-cell lung cancer, breast cancer, and acute leukemia. Various nanocarriers, including liposomes, have been exploited for targeted delivery of TPT. However, there are a number of challenges with TPT delivery using TPT liposomes (TLs), such as low encapsulation efficiency, physiological pH labile E ring (hydrolysis), accelerated blood clearance, multidrug
resistance, and cancer metastases. This review discusses these problems and the means to overcome them, including modification of TLs using zwitterionic poly(carboxybetaine), prolongation in dosing interval (long-term therapy), and modified liposomal encapsulation techniques including active loading methods. We also explore engineered TLs (surface and integral modifications) such as PEGylated TLs, ligand-anchored TLs, and stimuli-sensitive TLs. Further, potential applications, manifestations at the molecular level, patents granted,
and preclinical and clinical outlook for TLs are discussed.
PB Begell House
LK https://www.dl.begellhouse.com/journals/3667c4ae6e8fd136,32696049743c3c0f,4431255e7f1c66fe.html